Heart, Lung and Circulation
Abstract| Volume 20, ISSUE 4, P259-260, April 2011

Update on Atacas: A Randomised Trial of Aspirin and Tranexamic Acid in Coronary Artery Surgery

      Introduction: Aspirin is associated with increased bleeding during and after cardiac surgery, but it may also reduce thrombotic complications. We do not know whether there is a net benefit or risk from stopping aspirin. Antifibrinolytics such as tranexamic acid can reduce bleeding after cardiac surgery, but we do not know whether antifibrinolytics increase the risk of thrombotic complications such as MI or stroke. There are no large randomised trials to guide our practice [
      • Myles P.S.
      Aprotinin and lysine analogs in high-risk cardiac surgery.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Myles P.S.
        Aprotinin and lysine analogs in high-risk cardiac surgery.
        N Engl J Med. 2008;
        • Myles P.S.
        • Smith J.
        • Knight J.
        • Cooper D.J.
        • Silbert B.
        • McNeil J.
        • et al.
        Aspirin and tranexamic acid for coronary artery surgery (ATACAS) trial: rationale and design.
        Am Heart J. 2009;